Sign In
Buy BAYRY
$13.89
-0.110 (-0.786%)
At Close: Jul 31, 2026
Bayer confirms outlook despite slow businesses in agriculture, consumer health
12:55pm, Monday, 22'nd Apr 2024
Bayer on Monday confirmed its full-year guidance for earnings and cash flow despite slow business at its crop science and consumer health divisions.
Bayer's patent for blood thinner Xarelto invalid, UK court rules
10:26am, Friday, 12'th Apr 2024
Bayer's patent covering its best-selling blood thinner Xarelto is invalid, London's High Court ruled on Friday in a blow to the German drugmaker.
Bayer's Consumer Health Division Announces Changes to North America Leadership Team
08:01am, Tuesday, 09'th Apr 2024
WHIPPANY, N.J.--(BUSINESS WIRE)--Today, Bayer announced Samantha Avivi as the new Chief Marketing Officer (CMO) for its Consumer Health division in North America. She will report directly to Dave Toma
Google partners with Bayer on new AI product for radiologists
08:00am, Tuesday, 09'th Apr 2024
Google Cloud and Bayer are building a new AI-powered platform to help radiologists work more efficiently.
Judge slashes Bayer $1.56 billion Roundup verdict to $611 million
05:00pm, Friday, 05'th Apr 2024
A Missouri judge slashed a $1.56 billion verdict against Bayer to $611 million for three people who claimed its Roundup weed killer caused their cancer, by reducing punitive damages. Bayer said on Fri
Federman & Sherwood Investigates Bayer Heritage Federal Credit Union for Data Breach
03:47pm, Tuesday, 02'nd Apr 2024
OKLAHOMA CITY--(BUSINESS WIRE)-- #FedermanSherwood--Federman & Sherwood Investigates Bayer Heritage Federal Credit Union for Data Breach.
2 More Potential Biotech Buyout Targets
01:07pm, Monday, 25'th Mar 2024
M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related produ
Bayer (BAYRY) Banks on Pipeline Progress Amid Challenges
11:05am, Monday, 25'th Mar 2024
Bayer (BAYRY) relies on pipeline candidate elinzanetant and key drugs, Nubeqa and Kerendia, to drive growth amid pipeline and regulatory setbacks.
Bayer says 2024 sales of prostate cancer drug above $1 bln
08:07am, Thursday, 21'st Mar 2024
Bayer on Thursday predicted at least $1 billion in 2024 sales for prostate cancer drug Nubeqa, which is playing a bigger role for the drugmaker's growth prospects after the failure of a promising anti
Bayer's (BAYRY) Elinzanetant Meets Goals in Third Phase III Study
03:01pm, Wednesday, 20'th Mar 2024
Bayer's (BAYRY) pipeline candidate, elinzanetant, achieves primary and secondary goals in late-stage OASIS 3 study supporting submissions for marketing authorization.
Bayer to seek approval for menopausal relief drug after third trial win
03:36am, Tuesday, 19'th Mar 2024
Bayer said on Tuesday that it would request regulatory approval for its menopause drug after the daily pill was shown to ease hot flashes in a third late-stage trial, providing some relief for its pha
Bayer CEO: Roundup is 'safe,' and litigation is driving prices up
12:04pm, Saturday, 16'th Mar 2024
Life sciences company Bayer (BAYRY, BAYN.DE) isn't breaking itself up right now.
Bayer CEO on turnaround strategy: We've taken out multiple levels of hierarchy
11:05am, Tuesday, 12'th Mar 2024
Bayer CEO Bill Anderson joins 'Squawk on the Street' to discuss why the company hasn't broken up parts of the business, why the current strategy is the best way to go, and more.
Bayer (BAYRY) Q4 Earnings Top, Crop Science Unit Drives Revenues
10:51am, Wednesday, 06'th Mar 2024
Bayer (BAYRY) beats earnings estimates in the fourth quarter of 2023, primarily driven by increased sales of Crop Science and Pharmaceuticals products.
Bayer (BAYRY) Acquires BridgeBio's Cardiovascular Drug
02:01pm, Tuesday, 05'th Mar 2024
Bayer (BAYRY) acquires exclusive marketing rights for cardiovascular drug acoramidis in Europe from BridgeBio for an upfront payment of $310 million.
